Evaluation of the immune effector function and potency of the three selected Rebmab200 clones was based on ADCC activity with two NaPi2b positive ovarian cancer cells lines, OVCAR-3 and SK-OV-6. Here, SLC34A2 is linked to ovarian carcinoma.